Sartorius Stedim Biotech SA (DIM) - Total Liabilities
Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has total liabilities worth €4.05 Billion EUR (≈ $4.73 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sartorius Stedim Biotech SA - Total Liabilities Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech SA's total liabilities have evolved over time, based on quarterly financial data. See Sartorius Stedim Biotech SA current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Sartorius Stedim Biotech SA Competitors by Total Liabilities
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Roku Inc
NASDAQ:ROKU
|
USA | $1.68 Billion |
|
Fabrinet
NYSE:FN
|
USA | $947.60 Million |
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs70.66 Billion |
|
VAT Group AG
SW:VACN
|
Switzerland | CHF663.12 Million |
|
Inner Mongolia BaoTou Steel Union Co Ltd
SHG:600010
|
China | CN¥94.00 Billion |
|
Hua Nan Financial Holdings Co Ltd
TW:2880
|
Taiwan | NT$4.02 Trillion |
|
Hua Xia Bank Co Ltd
SHG:600015
|
China | CN¥4.47 Trillion |
|
Bank of Ireland Group PLC
IR:BIRG
|
Ireland | €149.31 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Sartorius Stedim Biotech SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sartorius Stedim Biotech SA stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sartorius Stedim Biotech SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sartorius Stedim Biotech SA (2005–2025)
The table below shows the annual total liabilities of Sartorius Stedim Biotech SA from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.89 Billion ≈ $4.55 Billion |
-8.06% |
| 2024-12-31 | €4.23 Billion ≈ $4.95 Billion |
-16.46% |
| 2023-12-31 | €5.07 Billion ≈ $5.92 Billion |
+98.60% |
| 2022-12-31 | €2.55 Billion ≈ $2.98 Billion |
+15.03% |
| 2021-12-31 | €2.22 Billion ≈ $2.59 Billion |
+39.80% |
| 2020-12-31 | €1.59 Billion ≈ $1.85 Billion |
+146.80% |
| 2019-12-31 | €642.79 Million ≈ $751.49 Million |
+22.07% |
| 2018-12-31 | €526.59 Million ≈ $615.64 Million |
+0.41% |
| 2017-12-31 | €524.45 Million ≈ $613.14 Million |
+21.32% |
| 2016-12-31 | €432.29 Million ≈ $505.40 Million |
+3.19% |
| 2015-12-31 | €418.92 Million ≈ $489.76 Million |
+13.76% |
| 2014-12-31 | €368.25 Million ≈ $430.52 Million |
-5.43% |
| 2013-12-31 | €389.39 Million ≈ $455.24 Million |
+8.42% |
| 2012-12-31 | €359.14 Million ≈ $419.88 Million |
+10.49% |
| 2011-12-31 | €325.04 Million ≈ $380.00 Million |
+11.59% |
| 2010-12-31 | €291.27 Million ≈ $340.52 Million |
+6.05% |
| 2009-12-31 | €274.66 Million ≈ $321.10 Million |
-2.15% |
| 2008-12-31 | €280.70 Million ≈ $328.16 Million |
+0.98% |
| 2007-12-31 | €277.96 Million ≈ $324.97 Million |
+33.37% |
| 2006-12-31 | €208.41 Million ≈ $243.65 Million |
-2.69% |
| 2005-12-31 | €214.18 Million ≈ $250.39 Million |
-- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more